DaVita, the largest U.S. provider of kidney care services, is exploring a sale of its physician network business, DaVita Medical Group, that could value the unit up to $4 billion, people familiar with the matter told Reuters on Wednesday.
The deliberations are still in their preliminary stages, and DaVita may decide not to go through with a sale, the sources said, asking not to be identified because the matter is confidential.
DaVita Medical Group could attract interest from a variety of bidders, including private equity firms and health insurers, the people said.
DaVita did not immediately respond to a request for comment. The company is working with investment bank Goldman Sachs on the potential sale, the people added. Goldman declined comment.